| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
49 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
1 |
| Net Income (TTM) (Millions $) |
-103 |
| Cash Flow (TTM) (Millions $) |
-57 |
| Capital Exp. (TTM) (Millions $) |
2 |
Business Description
PhaseBio Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of novel therapies for cardiovascular diseases and other rare genetic disorders. The company utilizes a proprietary technology called elastin-like polypeptides (ELPs) to engineer biologic drugs with improved properties such as extended half-life and targeted delivery.
PhaseBio's lead product candidate is PB2452, which is being developed as an antidote for the reversal of the antiplatelet effects of ticagrelor, a commonly used medication to prevent blood clots in patients with acute coronary syndrome. PB2452 has received breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) and is currently in late-stage clinical trials.
Additionally, PhaseBio is investigating other product candidates based on its ELP platform, including PB1046, a once-weekly therapy for pulmonary arterial hypertension, and PB6440, a potential treatment for phenylketonuria. The company collaborates with pharmaceutical companies and academic institutions to advance its research and development efforts.
Overall, PhaseBio Pharmaceuticals is dedicated to addressing unmet medical needs and improving outcomes for patients with cardiovascular diseases and rare genetic disorders through its innovative approach to drug development.
Company Address: 1 Great Valley Parkway Malvern 19355 PA
Company Phone Number: 981-6500 Stock Exchange / Ticker: NASDAQ PHAS
|
%